Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127503 · ClinicalTrials.gov registry record · Phase 2
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
A Phase 2 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01127503 is a Phase 2 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 2 participants.
The verdict
NCT01127503, a Phase 2 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with velocardiofacial syndrome (VCFS).
Interventions
- DRUG Placebo
- DRUG Metyrosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01127503
The ClinicalTrials.gov registry entry for NCT01127503 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01127503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01127503 about?
NCT01127503 is a clinical study titled "Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome". This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with velocardiofacial syndrome (VCFS).
What is the current status of trial NCT01127503?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2010-06. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01127503?
The interventions under investigation include: Placebo (DRUG), Metyrosine (DRUG).
Who is sponsoring clinical trial NCT01127503?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.